At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CLSD Clearside Biomedical
Trading 01-10 12:49:48 EST
0.9560
-0.0168
-1.73%
High0.9917
Low0.9500
Vol56.96K
Open0.9709
D1 Closing0.9728
Amplitude4.29%
Mkt Cap72.51M
Tradable Cap67.13M
Total Shares75.84M
T/O55.14K
T/O Rate0.08%
Tradable Shares70.22M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Further weakness as Clearside Biomedical (NASDAQ:CLSD) drops 14% this week, taking five-year losses to 72%
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.